CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Teriparatide (rDNA origin) injection

Last Updated: December 18, 2008
Result type: Reports
Project Number: SR0152-000
Product Line: Reimbursement Review

Generic Name: Teriparatide (rDNA origin) injection

Brand Name: Forteo

Manufacturer: Eli Lilly Canada Inc.

Therapeutic Area: Osteoporosis, glucocorticoid induced

Indications: Osteoporosis, glucocorticoid induced

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 22, 2009

Recommendation Type: Do not list